Immunocord

Company Overview

Snapshot

Founded in February 2016 by Amnon Pelz, Immunocord operates with 1–10 employees. The company is currently in a Pre-Funding stage.

Business overview

Immunocord is a Health Tech & Life Sciences company focused on developing advanced medical technologies. The company specializes in graft engineering of cord blood to enhance adoptive immunotherapy, specifically targeting solid tumors. Immunocord's core technology aims to improve treatment outcomes in oncology, serving the healthcare sector with a B2B business model.

Company Intelligence Q&A

What is Immunocord's primary focus?

Immunocord focuses on graft engineering of cord blood for enhanced adoptive immunotherapy against solid tumors, operating within the Health Tech & Life Sciences sector.

Who founded Immunocord?

Immunocord was founded by Amnon Pelz in February 2016.

What is Immunocord's current employee count?

Immunocord currently has 1–10 employees.

What is Immunocord's business model?

Immunocord operates with a B2B business model, targeting healthcare providers.

What is Immunocord's current product development status?

Immunocord is currently in the customer development stage for its products, focusing on refining its graft engineering solution for enhanced adoptive immunotherapy against solid tumors.